Klivira
Request demo

Streamlining Pediatric Oncology Specialty Drug Prior Auth

Navigating pediatric oncology specialty drug prior auth is a critical, often complex process that demands precision and speed to ensure timely access to life-saving treatments. Klivira streamlines this workflow, reducing administrative burden and accelerating therapy initiation for childhood cancer patients.

For revenue cycle directors and prior authorization coordinators in pediatric oncology, managing specialty drug prior authorizations presents unique challenges. The high cost, rapid clinical evolution of therapies like CAR-T, and the emotional urgency of childhood cancer care necessitate an efficient, accurate PA process. Klivira's platform is engineered to address these specific demands.

The Unique Demands of Pediatric Oncology Prior Authorization

Pediatric oncology treatments often involve complex, high-cost therapies, including specialized chemotherapy regimens, CAR-T cell therapies, and advanced modalities like proton beam therapy. These interventions are frequently guided by Cooperative Oncology Group (COG) protocols, requiring stringent documentation and rapid approval to maintain treatment timelines. Delays in prior authorization for these specialty drugs can have profound impacts on patient outcomes and family well-being.

Challenges in Specialty Drug PA for Childhood Cancers

The workflow for specialty drug prior authorization in pediatric oncology is fraught with potential points of friction. Determining whether a prescribed biologic or targeted therapy falls under the medical or pharmacy benefit is a common initial hurdle, often leading to benefit-side misclassification and subsequent PA submission to the wrong channel. Further complexities arise from payer-specific site-of-care policies, step-therapy requirements, and the intricate coordination with specialty pharmacies for fulfillment, all of which can introduce significant delays.

Klivira's Automated Approach to Pediatric Oncology Specialty Drug PA

  • **Automated Benefit-Side Determination**: Klivira's policy engine automatically identifies the correct benefit side (medical vs. pharmacy) for each specialty drug, per payer and patient context, preventing misclassification errors.
  • **Multi-Channel Routing**: Pharmacy-benefit specialty drugs route via ePA partners like CoverMyMeds and Surescripts using NCPDP SCRIPT ePA, while medical-benefit drugs utilize channels such as provider portals, X12 278, or Da Vinci PAS where available.
  • **Step-Therapy & Clinical Documentation**: The platform reads medication history and treatment response data from FHIR MedicationRequest and Observation resources, automating the population of essential step-therapy documentation.
  • **Site-of-Care Policy Adherence**: Klivira's logic incorporates payer site-of-care policies, flagging potential mismatches before submission and helping align the PA with payer requirements, especially for infused agents.
  • **Specialty Pharmacy Handoff Coordination**: For pharmacy-benefit drugs, Klivira coordinates the post-approval specialty pharmacy fulfillment workflow, minimizing delays in medication delivery.

EMR Integration and Data Utilization

Klivira integrates seamlessly with leading EMR systems, leveraging SMART on FHIR capabilities to extract critical clinical data. This includes diagnosis codes, prior-line therapy history, and specific J-codes or HCPCS codes relevant to pediatric oncology treatments. This integration ensures that PA submissions are complete, accurate, and aligned with clinical guidelines from bodies like NCCN and ASCO, which often inform payer policies for oncology drugs.

Impact on Revenue Cycle and Patient Care

By automating the pediatric oncology specialty drug prior authorization process, Klivira significantly reduces the manual burden on PA coordinators, allowing them to focus on complex cases and patient advocacy. This automation leads to fewer denials, faster turnaround times, and ultimately, more predictable revenue cycles and expedited access to critical therapies for children battling cancer. While Klivira identifies manufacturer copay assistance program availability, it's crucial for organizations to consult their compliance teams regarding interactions, particularly for Medicare patients.

Frequently asked questions

How does Klivira handle the medical versus pharmacy benefit split for pediatric oncology specialty drugs?

Klivira's platform includes an automated benefit-side determination engine that identifies whether a specific specialty drug for a pediatric oncology patient falls under the medical or pharmacy benefit for their payer. This ensures that the prior authorization request is routed to the correct channel from the outset, preventing delays from misclassification.

What specific pediatric oncology treatments benefit most from Klivira's specialty drug PA automation?

Klivira's automation is particularly beneficial for high-cost, high-complexity pediatric oncology treatments such as CAR-T cell therapies, advanced chemotherapy regimens, and other specialty biologics or oral targeted therapies. It streamlines the PA process for these critical interventions, ensuring timely approval and access.

How does Klivira integrate with our EMR to gather necessary clinical documentation for pediatric oncology PA?

Klivira integrates with your EMR via SMART on FHIR, allowing it to securely extract relevant clinical data such as diagnosis codes, medication history (from FHIR MedicationRequest), and treatment response data (from FHIR Observation resources). This data is then used to automatically populate prior authorization forms, ensuring comprehensive and accurate submissions.

Does Klivira assist with site-of-care requirements for infused pediatric oncology specialty drugs?

Yes, Klivira's system incorporates payer site-of-care policies into its logic. Before submission, it will surface information if a payer's policy requires an alternative site of care (e.g., infusion center instead of hospital outpatient) for a specific medical-benefit specialty drug, helping to ensure compliance and avoid denials.

What role does Klivira play in coordinating with specialty pharmacies after PA approval?

For pharmacy-benefit specialty drugs, Klivira coordinates the post-approval workflow with the payer's specialty pharmacy partners (e.g., Accredo, CVS Specialty, Optum Specialty). This coordination helps streamline the handoff process, reducing the time from PA approval to medication fulfillment and patient delivery.

Related coverage

Other pediatric-oncology prior auth workflows

Ready to automate this workflow for this specialty?

See how Klivira automates prior authorizations for your team.

Request a demo